Skip to main content
. Author manuscript; available in PMC: 2013 Sep 30.
Published in final edited form as: Oncogene. 2008 Oct 13;28(2):306–312. doi: 10.1038/onc.2008.384

Figure 3.

Figure 3

B7-H1 and phospho-AKT are expressed in breast and prostate carcinoma samples with activated PI(3)K. Patient samples were characterized histologically and classified on the basis of PI(3)K activation, either through PTEN loss or PIK3CA mutation. Representative histology slides are shown. (a) PI(3)K low-activity breast carcinoma shows minimal to no staining with B7-H1-specific antibody, (b) PI(3)K high-activity breast carcinoma shows positive staining, (c) PI(3)K low-activity breast carcinoma shows minimal to no staining with phopsho-AKT-specific antibody (d) B7-H1-positive breast carcinoma sample shows positive staining for phospho-AKT. (e) PI(3)K low-activity prostate carcinoma shows minimal to no staining with B7-H1-specific antibody, (f) PI(3)K high-activity prostate carcinoma shows positive staining, (g) PI(3)K low-activity prostate carcinoma shows minimal to no staining with phopsho-AKT-specific antibody, (h) B7-H1-positive prostate carcinoma sample shows positive staining for phospho-AKT.